Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

across solid tumors with high microsatellite instability status as well as for Keytruda combined with Eisai and Merck’s ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

The data from the KEYNOTE-581/CLEAR study reveal that the combination of PD-1 inhibitor Keytruda (pembrolizumab) with Eisai’s targeted tyrosine kinase inhibitor Lenvima (lenvatinib) reduced the ...

Scotland has become the first country in the UK to back NHS funding for the use of Merck & Co/MSD's Keytruda in combination with Eisai's Lenvima as a treatment for advanced or recurrent ...

According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...

Former Democratic congresswoman Tulsi Gabbard has been appointed as the director of national intelligence by US President-elect Donald Trump. Gabbard, who switched to the Republican Party, is a ...